Baudax Bio, Inc. (NASDAQ:BXRX) has a beta value of 0 and has seen 1,668,654 shares traded in the recent trading session. The company, currently valued at $73.75 Million, closed the recent trade at $1.03 per share which meant it lost -$0.08 on the day or -6.81% during that session. The BXRX stock price is -380.58% off its 52-week high price of $4.95 and 5.83% above the 52-week low of $0.97. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.35 Million shares traded. The 3-month trading volume is 5.99 Million shares.
The consensus among analysts is that Baudax Bio, Inc. (BXRX) is a Buy stock at the moment, with a recommendation rating of 1.7. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 3 have rated it as a Hold, with 3 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.19.
Baudax Bio, Inc. (NASDAQ:BXRX) trade information
Despite being -6.81% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Thursday, Apr 29 when the BXRX stock price touched $1.1602 or saw a rise of 11.22%. Year-to-date, Baudax Bio, Inc. shares have moved 1.98%, while the 5-day performance has seen it change -5.5%. Over the past 30 days, the shares of Baudax Bio, Inc. (NASDAQ:BXRX) have changed -23.13%. Short interest in the company has seen 4.36 Million shares shorted with days to cover at 0.73.
Wall Street analysts have a consensus price target for the stock at $4.67, which means that the shares’ value could jump 353.4% from the levels at last check today. The projected low price target is $3 while the price target rests at a high of $6. In that case, then, we find that the latest price level in today’s session is +482.52% off the targeted high while a plunge would see the stock lose 191.26% from the levels at last check today.
Baudax Bio, Inc. (BXRX) estimates and forecasts
Figures show that Baudax Bio, Inc. shares have outperformed across the wider relevant industry. The company’s shares have lost -1.77% over the past 6 months, with this year growth rate of 84.48%, compared to 16.6% for the industry. Other than that, the company has, however, increased its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are 95.3% and 90.7% for the next quarter. Revenue growth from the last financial year stood is estimated to be +2218.5%.
Earnings growth for 2021 is a modest -12.9%.
Baudax Bio, Inc. (NASDAQ:BXRX)’s Major holders
Insiders own 0.84% of the company shares, while shares held by institutions stand at 17.26% with a share float percentage of 17.41%. Investors are also buoyed by the number of investors in a company, with Baudax Bio, Inc. having a total of 49 institutions that hold shares in the company. The top two institutional holders are Armistice Capital, LLC with over 3.5 Million shares worth more than $3.54 Million. As of December 30, 2020, Armistice Capital, LLC held 4.99% of shares outstanding.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The other major institutional holder is Vanguard Group, Inc. (The), with the holding of over 495.21 Thousand shares as of December 30, 2020. The firm’s total holdings are worth over $500.16 Thousand and represent 0.71% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of December 30, 2020, the former fund manager holds about 0.38% shares in the company for having 268717 shares of worth $271.4 Thousand while later fund manager owns 197.09 Thousand shares of worth $199.06 Thousand as of December 30, 2020, which makes it owner of about 0.28% of company’s outstanding stock.